Phase 2Data readout

AAV2-hAQP1

Radiation-Induced Xerostomia

MGTXMeiraGTx

Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset: AAV2-hAQP1
Development stage: Phase 2
Event type: Data readout
Indication: Radiation-Induced Xerostomia

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for AAV2-hAQP1 in Radiation-Induced Xerostomia. The expected timing is based on the latest available company guidance and may change.

Development notes

05/14/26:- AQUAx2 is closing; pivotal 12-month data readout remains on track for Q2 2027. 08/13/26:- Positive Ph1 three-year data and Breakthrough Therapy Designation were reported. AQUAx2 Ph2 readout will occur in Q2 2027; BLA filing may occur Mid-2027; approval is targeted for end 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source